Gupta Dhruv Sanjay, Suares Divya
Department of Pharmaceutical Sciences, Shobhaben Pratapbhai Patel School of Pharmacy & Technology, Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai, 400056, India.
Pharm Nanotechnol. 2025;13(1):155-170. doi: 10.2174/0122117385286781240228060152.
Lung cancer, a leading cause of cancer-related deaths globally, is gaining research interest more than ever before. Owing to the burden of pathogenesis on the quality of life of patients and subsequently the healthcare system, research efforts focus on its management and amelioration. In an effort to improve bioavailability, enhance stability, minimize adverse effects and reduce the incidence of resistance, nanotechnological platforms have been harnessed for drug delivery and improving treatment outcomes. Lipid nanoparticles, in particular, offer an interesting clinical opportunity with respect to the delivery of a variety of agents. These include synthetic chemotherapeutic agents, immunotherapeutic molecules, as well as phytoconstituents with promising anticancer benefits. In addition to this, these systems are being studied for their usage in conjunction with other treatment strategies. However, their applications remain limited owing to a number of challenges, chiefly clinical translation. There is a need to address the scalability of such technologies, in order to improve accessibility. The authors aim to offer a comprehensive understanding of the evolution of lipid nanoparticles and their application in lung cancer, the interplay of disease pathways and their mechanism of action and the potential for delivery of a variety of agents. Additionally, a discussion with respect to results from preclinical studies has also been provided. The authors have also provided a well-rounded insight into the limitations and future perspectives. While the possibilities are endless, there is a need to undertake focused research to expedite clinical translation and offer avenues for wider applications in disease management.
肺癌是全球癌症相关死亡的主要原因之一，正比以往任何时候都更受研究关注。由于发病机制给患者生活质量以及随后的医疗保健系统带来负担，研究工作集中在其管理和改善方面。为了提高生物利用度、增强稳定性、将不良反应降至最低并降低耐药发生率，纳米技术平台已被用于药物递送并改善治疗效果。特别是脂质纳米颗粒，在递送多种药物方面提供了一个有趣的临床机会。这些药物包括合成化疗药物、免疫治疗分子以及具有抗癌益处的植物成分。除此之外，正在研究这些系统与其他治疗策略联合使用的情况。然而，由于一些挑战，主要是临床转化问题，它们的应用仍然有限。有必要解决此类技术的可扩展性问题，以提高可及性。作者旨在全面介绍脂质纳米颗粒的发展及其在肺癌中的应用、疾病途径的相互作用及其作用机制以及递送多种药物的潜力。此外，还提供了关于临床前研究结果的讨论。作者还对局限性和未来前景进行了全面深入的分析。虽然可能性无穷，但需要进行有针对性的研究，以加快临床转化，并为疾病管理中的更广泛应用提供途径。
